You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
Joint Survey from National Osteoporosis Foundation, HealthyWomen and Radius Health Sounds an Urgent Call to Action for Women to Know Their Risk, Get the Facts ‘Fractured Truth' Education Campaign Addresses Entrenched Misperceptions, Asks Women to Rethink Their Beliefs About Bone Health WALTHAM,
Radius partner Teijin Pharma has submitted a New Drug Application for abaloparatide-SC for treatment of osteoporosis in Japan WALTHAM, Mass. , May 27, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that its partner, Teijin Pharma Limited
Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer CAMBRIDGE, Mass., April 20, 2011— Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health
Radius Initiates Human Pharmacokinetic Study of Optimized Transdermal Patch of Investigational Drug Abaloparatide WALTHAM, Mass., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), today announced that the European Medicines Agency (EMA) has validated for review the Marketing
WALTHAM, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that its New Drug Application (NDA)
Radius Announces Follow-Up on the Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis WALTHAM, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ( RDUS ) today announced a series of follow-ups on the positive
Study Meets Primary Endpoint of Reducing the Percentage of Patients with Incident Vertebral Fracture and Also Meets Important Secondary Endpoints: Adverse Events Consistent with Previous Clinical Experience Radius Remains on Track for Completion of the Ongoing 6-Month ACTIVExtend Study and NDA